Modern science offers a novel strategy to target the most challenging infections fueled by biofilms. Learn more about our important work to combat these infections and reduce antibiotic resistance.Our Science An innovative, strategically focused management team with deep anti-infective therapeutic and vaccine development expertise.Meet The Team In the News Clarametyx Initiates Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101 Against Community-Acquired Bacterial PneumoniaNovember 30, 2022 Clarametyx Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101October 5, 2022 CARB-X Awards Clarametyx Biosciences $3.89 Million in Additional Option Funding to Accelerate Anti-biofilm Technology for Life-threatening Bacterial InfectionsApril 4, 2022 Clarametyx Biosciences Awarded $3.15 Million Grant From NIH to Advance a Broad-spectrum Vaccine Technology for Bacterial InfectionsDecember 20, 2021